Immunology
Immune system disorders affect hundreds of millions of people worldwide and can severely impact quality of life and even life expectancy1,2,3 . These debilitating disorders include those affecting the joints (such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis), the skin (such as psoriasis) and the gut (such as Crohn’s disease and ulcerative colitis).
Sandoz is the long-term partner supporting rheumatologists, dermatologists and gastroenterologists in advancing patient care without compromise. Our proven expertise and experience in biosimilars delivers high-quality affordable medicines in this therapy area.
We are committed to providing life-changing immunology therapies and have a robust biosimilar immunology portfolio with Erelzi®4, Hyrimoz®5, Zessly®6 and Rixathon®7.
| Sandoz biosimilar | Indication area |
|---|---|
| Hyrimoz® [adalimumab] | Immunology (rheumatology, gastroenterology, dermatology) |
| Zessly® [infliximab] |
Immunology (rheumatology, gastroenterology, dermatology) |
| Erelzi® [etanercept] | Immunology (rheumatology, dermatology) |
Endocrinology
Endocrinology diseases fall under a broad category of over or underproduction of hormones, altered tissue response to hormones or tumors arising from endocrine tissue1. Some of these disorders can affect metabolism such as diabetes mellitus - with steadily increasing prevalence worldwide2 - and impair fertility and growth.
Sandoz is committed to the Endocrinology community, supporting healthcare professionals and patient care givers. Sandoz is also focused on increasing physician and patient access to broader options for high-quality biologic medicines in Endocrinology.
We currently market Omnitrope® (recombinant human growth hormone, rhGH, Somatropin), which was first approved in Australia in 20043*, then approved by the EMA in 2006.4
In addition, we are working on bringing multiple insulin biosimilars to the market in the next couple of years. 5
| Sandoz biosimilar | Indication area |
|---|---|
| Omnitrope® [somatropin] |
Endocrinology |
Oncology
Cancer cases are predicted to almost double across the globe by 2024 to an estimated 668,535 per day. This will lead to a major rise in healthcare spending.1 A deeper understanding of oncology is leading to increasing numbers of new cancer drugs, often at a high cost, resulting in spending that exceeds current budgets, threatening future resources for cancer care.
Biosimilars are key to creating a more sustainable future in cancer care and are estimated to save €8-10 billion annually in the EU.2 Sandoz is proudly committed to helping shape this future.
We currently market Zarzio®3 / Zarxio®4, Binocrit®5 and Ziextenzo®6, used in supportive cancer care, and Rixathon®7/Riximyo®8 to treat blood cancers. Sandoz also has a robust portfolio of proposed oncology biosimilars (trastuzumab and bevacizumab) we are bringing to market in the future.
Sandoz offers a comprehensive portfolio of oncology medicines with more than 50 medicines for the treatment of a wide range of cancers, including chemotherapeutics, biologics, hormones, and supportive care treatments.9
| Sandoz biosimilar | Indication area |
|---|---|
| Binocrit® [epoetin alfa] |
Oncology (supportive cancer care) |
| Zarzio®/ Zarxio® [filgrastim] |
Oncology (supportive cancer care) |
| Ziextenzo® [pegfilgrastim] |
Oncology (supportive cancer care) |
| Rixathon® [rituximab] |
Oncology (blood cancers), Immunology (rheumatology) |